

Drugs for Chronic Obstructive Pulmonary Disorder Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

<https://marketpublishers.com/r/D51CC2175ECFEN.html>

Date: January 2020

Pages: 97

Price: US\$ 3,000.00 (Single User License)

ID: D51CC2175ECFEN

Abstracts

SUMMARY

Further key aspects of the report indicate that:

Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology

Chapter 2: Global Industry Summary

Chapter 3: Market Dynamics

Chapter 4: Global Market Segmentation by region, type and End-Use

Chapter 5: North America Market Segmentation by region, type and End-Use

Chapter 6: Europe Market Segmentation by region, type and End-Use

Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use

Chapter 8: South America Market Segmentation by region, type and End-Use

Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.

Chapter 10: Market Competition by Companies

Chapter 11: Market forecast and environment forecast.

Chapter 12: Industry Summary.

The global Drugs for Chronic Obstructive Pulmonary Disorder market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for @@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.

Based on the type of product, the global Drugs for Chronic Obstructive Pulmonary Disorder market segmented into

Short-Acting Bronchodilators

Corticosteroids

Methylxanthines

Long-Acting Bronchodilators

Phosphodiesterase-4 Inhibitors

Based on the end-use, the global Drugs for Chronic Obstructive Pulmonary Disorder market classified into

GOLD 1? FEV1 ? 80%

GOLD 2? 50% ? FEV1

GOLD 3? 30% ? FEV1

GOLD 4? FEV1

Based on geography, the global Drugs for Chronic Obstructive Pulmonary Disorder market segmented into

North America [U.S., Canada, Mexico]

Europe [Germany, UK, France, Italy, Rest of Europe]

Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]

South America [Brazil, Argentina, Rest of Latin America]

Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]

And the major players included in the report are

AstraZeneca

Boehringer Ingelheim

GSK

Novartis

Teva Pharmaceuticals

Ache Laboratorios Farmaceuticos

Almirall

Aquinox Pharmaceuticals

Ario Pharma

Asmacure

Astellas Pharma

BioMarck Pharmaceuticals

Contents

1 RESEARCH SCOPE

- 1.1 Research Product Definition
- 1.2 Research Segmentation
 - 1.2.1 Product Type
 - 1.2.2 Main product Type of Major Players
- 1.3 Demand Overview
- 1.4 Research Methodology

2 GLOBAL DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER INDUSTRY

- 2.1 Summary about Drugs for Chronic Obstructive Pulmonary Disorder Industry
- 2.2 Drugs for Chronic Obstructive Pulmonary Disorder Market Trends
 - 2.2.1 Drugs for Chronic Obstructive Pulmonary Disorder Production & Consumption Trends
 - 2.2.2 Drugs for Chronic Obstructive Pulmonary Disorder Demand Structure Trends
- 2.3 Drugs for Chronic Obstructive Pulmonary Disorder Cost & Price

3 MARKET DYNAMICS

- 3.1 Manufacturing & Purchasing Behavior in 2020
- 3.2 Market Development under the Impact of COVID-19
 - 3.2.1 Drivers
 - 3.2.2 Restraints
 - 3.2.3 Opportunity
 - 3.2.4 Risk

4 GLOBAL MARKET SEGMENTATION

- 4.1 Region Segmentation (2017 to 2021f)
 - 4.1.1 North America (U.S., Canada and Mexico)
 - 4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
 - 4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
 - 4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
 - 4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and

Africa)

4.2 Product Type Segmentation (2017 to 2021f)

4.2.1 Short-Acting Bronchodilators

4.2.2 Corticosteroids

4.2.3 Methylxanthines

4.2.4 Long-Acting Bronchodilators

4.2.5 Phosphodiesterase-4 Inhibitors

4.3 Consumption Segmentation (2017 to 2021f)

4.3.1 GOLD 1? FEV1 ? 80%

4.3.2 GOLD 2? 50% ? FEV1 4.3.3 GOLD 3? 30% ? FEV1 4.3.4 GOLD 4? FEV1

5 NORTH AMERICA MARKET SEGMENT

5.1 Region Segmentation (2017 to 2021f)

5.1.1 U.S.

5.1.2 Canada

5.1.3 Mexico

5.2 Product Type Segmentation (2017 to 2021f)

5.2.1 Short-Acting Bronchodilators

5.2.2 Corticosteroids

5.2.3 Methylxanthines

5.2.4 Long-Acting Bronchodilators

5.2.5 Phosphodiesterase-4 Inhibitors

5.3 Consumption Segmentation (2017 to 2021f)

5.3.1 GOLD 1? FEV1 ? 80%

5.3.2 GOLD 2? 50% ? FEV1 5.3.3 GOLD 3? 30% ? FEV1 5.3.4 GOLD 4? FEV1 5.4

Impact of COVID-19 in North America

6 EUROPE MARKET SEGMENTATION

6.1 Region Segmentation (2017 to 2021f)

6.1.1 Germany

6.1.2 UK

6.1.3 France

6.1.4 Italy

6.1.5 Rest of Europe

6.2 Product Type Segmentation (2017 to 2021f)

6.2.1 Short-Acting Bronchodilators

6.2.2 Corticosteroids

6.2.3 Methylxanthines

- 6.2.4 Long-Acting Bronchodilators
- 6.2.5 Phosphodiesterase-4 Inhibitors
- 6.3 Consumption Segmentation (2017 to 2021f)
 - 6.3.1 GOLD 1? FEV1 ? 80%
 - 6.3.2 GOLD 2? 50% ? FEV1
 - 6.3.3 GOLD 3? 30% ? FEV1
 - 6.3.4 GOLD 4? FEV1
- 6.4 Impact of COVID-19 in Europe

7 ASIA-PACIFIC MARKET SEGMENTATION

- 7.1 Region Segmentation (2017 to 2021f)
 - 7.1.1 China
 - 7.1.2 India
 - 7.1.3 Japan
 - 7.1.4 South Korea
 - 7.1.5 Southeast Asia
 - 7.1.6 Australia
 - 7.1.7 Rest of Asia Pacific
- 7.2 Product Type Segmentation (2017 to 2021f)
 - 7.2.1 Short-Acting Bronchodilators
 - 7.2.2 Corticosteroids
 - 7.2.3 Methylxanthines
 - 7.2.4 Long-Acting Bronchodilators
 - 7.2.5 Phosphodiesterase-4 Inhibitors
- 7.3 Consumption Segmentation (2017 to 2021f)
 - 7.3.1 GOLD 1? FEV1 ? 80%
 - 7.3.2 GOLD 2? 50% ? FEV1
 - 7.3.3 GOLD 3? 30% ? FEV1
 - 7.3.4 GOLD 4? FEV1
- 7.4 Impact of COVID-19 in Europe

8 SOUTH AMERICA MARKET SEGMENTATION

- 8.1 Region Segmentation (2017 to 2021f)
 - 8.1.1 Brazil
 - 8.1.2 Argentina
 - 8.1.3 Rest of Latin America
- 8.2 Product Type Segmentation (2017 to 2021f)
 - 8.2.1 Short-Acting Bronchodilators
 - 8.2.2 Corticosteroids
 - 8.2.3 Methylxanthines
 - 8.2.4 Long-Acting Bronchodilators

- 8.2.5 Phosphodiesterase-4 Inhibitors
- 8.3 Consumption Segmentation (2017 to 2021f)
 - 8.3.1 GOLD 1? FEV1 ? 80%
 - 8.3.2 GOLD 2? 50% ? FEV1
 - 8.3.3 GOLD 3? 30% ? FEV1
 - 8.3.4 GOLD 4? FEV1 8.4
- Impact of COVID-19 in Europe

9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION

- 9.1 Region Segmentation (2017 to 2021f)
 - 9.1.1 GCC
 - 9.1.2 North Africa
 - 9.1.3 South Africa
 - 9.1.4 Rest of Middle East and Africa
- 9.2 Product Type Segmentation (2017 to 2021f)
 - 9.2.1 Short-Acting Bronchodilators
 - 9.2.2 Corticosteroids
 - 9.2.3 Methylxanthines
 - 9.2.4 Long-Acting Bronchodilators
 - 9.2.5 Phosphodiesterase-4 Inhibitors
- 9.3 Consumption Segmentation (2017 to 2021f)
 - 9.3.1 GOLD 1? FEV1 ? 80%
 - 9.3.2 GOLD 2? 50% ? FEV1
 - 9.3.3 GOLD 3? 30% ? FEV1
 - 9.3.4 GOLD 4? FEV1 9.4
- Impact of COVID-19 in Europe

10 COMPETITION OF MAJOR PLAYERS

- 10.1 Brief Introduction of Major Players
 - 10.1.1 AstraZeneca
 - 10.1.2 Boehringer Ingelheim
 - 10.1.3 GSK
 - 10.1.4 Novartis
 - 10.1.5 Teva Pharmaceuticals
 - 10.1.6 Ache Laboratorios Farmaceuticos
 - 10.1.7 Almirall
 - 10.1.8 Aquinox Pharmaceuticals
 - 10.1.9 Ario Pharma
 - 10.1.10 Asmacure
 - 10.1.11 Astellas Pharma
 - 10.1.12 BioMarck Pharmaceuticals

10.2 Drugs for Chronic Obstructive Pulmonary Disorder Sales Date of Major Players (2017-2020e)

- 10.2.1 AstraZeneca
- 10.2.2 Boehringer Ingelheim
- 10.2.3 GSK
- 10.2.4 Novartis
- 10.2.5 Teva Pharmaceuticals
- 10.2.6 Ache Laboratorios Farmaceuticos
- 10.2.7 Almirall
- 10.2.8 Aquinox Pharmaceuticals
- 10.2.9 Ario Pharma
- 10.2.10 Asmacure
- 10.2.11 Astellas Pharma
- 10.2.12 BioMarck Pharmaceuticals

10.3 Market Distribution of Major Players

10.4 Global Competition Segmentation

11 MARKET FORECAST

- 11.1 Forecast by Region
- 11.2 Forecast by Demand
- 11.3 Environment Forecast
 - 11.3.1 Impact of COVID-19
 - 11.3.2 Geopolitics Overview
 - 11.3.3 Economic Overview of Major Countries

12 REPORT SUMMARY STATEMENT

List Of Tables

LIST OF TABLES

1. Table Drugs for Chronic Obstructive Pulmonary Disorder Product Type Overview
2. Table Drugs for Chronic Obstructive Pulmonary Disorder Product Type Market Share List
3. Table Drugs for Chronic Obstructive Pulmonary Disorder Product Type of Major Players
4. Table Brief Introduction of AstraZeneca
5. Table Brief Introduction of Boehringer Ingelheim
6. Table Brief Introduction of GSK
7. Table Brief Introduction of Novartis
8. Table Brief Introduction of Teva Pharmaceuticals
9. Table Brief Introduction of Ache Laboratorios Farmaceuticos
10. Table Brief Introduction of Almirall
11. Table Brief Introduction of Aquinox Pharmaceuticals
12. Table Brief Introduction of Ario Pharma
13. Table Brief Introduction of Asmacure
14. Table Brief Introduction of Astellas Pharma
15. Table Brief Introduction of BioMarck Pharmaceuticals
16. Table Products & Services of AstraZeneca
17. Table Products & Services of Boehringer Ingelheim
18. Table Products & Services of GSK
19. Table Products & Services of Novartis
20. Table Products & Services of Teva Pharmaceuticals
21. Table Products & Services of Ache Laboratorios Farmaceuticos
22. Table Products & Services of Almirall
23. Table Products & Services of Aquinox Pharmaceuticals
24. Table Products & Services of Ario Pharma
25. Table Products & Services of Asmacure
26. Table Products & Services of Astellas Pharma
27. Table Products & Services of BioMarck Pharmaceuticals
28. Table Market Distribution of Major Players
29. Table Global Major Players Sales Revenue (Million USD) 2017-2020e
30. Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e
31. Table Global Drugs for Chronic Obstructive Pulmonary Disorder Market Forecast (Million USD) by Region 2021f-2026f
32. Table Global Drugs for Chronic Obstructive Pulmonary Disorder Market Forecast (Million USD) Share by Region 2021f-2026f

33. Table Global Drugs for Chronic Obstructive Pulmonary Disorder Market Forecast (Million USD) by Demand 2021f-2026f

34. Table Global Drugs for Chronic Obstructive Pulmonary Disorder Market Forecast (Million USD) Share by Demand 2021f-2026f

List Of Figures

LIST OF FIGURES

1. Figure Global Drugs for Chronic Obstructive Pulmonary Disorder Market Size under the Impact of COVID-19, 2017-2021f (USD Million)
2. Figure Global Drugs for Chronic Obstructive Pulmonary Disorder Market by Region under the Impact of COVID-19, 2017-2021f (USD Million)
3. Figure Global Drugs for Chronic Obstructive Pulmonary Disorder Market by Product Type under the Impact of COVID-19, 2017-2021f (USD Million)
4. Figure Global Drugs for Chronic Obstructive Pulmonary Disorder Market by Demand under the Impact of COVID-19, 2017-2021f (USD Million)
5. Figure Global Drugs for Chronic Obstructive Pulmonary Disorder Production by Region under the Impact of COVID-19, 2021-2026 (USD Million)
6. Figure Global Drugs for Chronic Obstructive Pulmonary Disorder Consumption by Region under the Impact of COVID-19, 2021-2026 (USD Million)
7. Figure Global Drugs for Chronic Obstructive Pulmonary Disorder Consumption by Type under the Impact of COVID-19, 2021-2026 (USD Million)
8. Figure North America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
9. Figure Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
10. Figure Asia-Pacific Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
11. Figure South America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
12. Figure Middle East and Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
13. Figure Short-Acting Bronchodilators Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
14. Figure Corticosteroids Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
15. Figure Methylxanthines Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
16. Figure Long-Acting Bronchodilators Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
17. Figure Phosphodiesterase-4 Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
18. Figure GOLD 1? FEV1 ? 80% Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

19. Figure GOLD 2? 50% ? FEV1
20. Figure GOLD 3? 30% ? FEV1
21. Figure GOLD 4? FEV1
22. Figure U.S. Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
23. Figure Canada Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
24. Figure Mexico Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
25. Figure Short-Acting Bronchodilators Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
26. Figure Corticosteroids Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
27. Figure Methylxanthines Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
28. Figure Long-Acting Bronchodilators Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
29. Figure Phosphodiesterase-4 Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
30. Figure GOLD 1? FEV1 ? 80% Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
31. Figure GOLD 2? 50% ? FEV1
32. Figure GOLD 3? 30% ? FEV1
33. Figure GOLD 4? FEV1
34. Figure Germany Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
35. Figure UK Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
36. Figure France Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
37. Figure Italy Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
38. Figure Rest of Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
39. Figure Short-Acting Bronchodilators Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
40. Figure Corticosteroids Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
41. Figure Methylxanthines Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
42. Figure Long-Acting Bronchodilators Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
43. Figure Phosphodiesterase-4 Inhibitors Segmentation Market Size (USD Million)

- 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
44. Figure GOLD 1? FEV1 ? 80% Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
45. Figure GOLD 2? 50% ? FEV1 46. Figure GOLD 3? 30% ? FEV1 47. Figure GOLD 4? FEV1 48. Figure China Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
49. Figure India Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
50. Figure Japan Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
51. Figure South Korea Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
52. Figure Southeast Asia Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
53. Figure Australia Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
54. Figure Rest of Asia Pacific Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
55. Figure Short-Acting Bronchodilators Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
56. Figure Corticosteroids Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
57. Figure Methylxanthines Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
58. Figure Long-Acting Bronchodilators Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
59. Figure Phosphodiesterase-4 Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
60. Figure GOLD 1? FEV1 ? 80% Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
61. Figure GOLD 2? 50% ? FEV1 62. Figure GOLD 3? 30% ? FEV1 63. Figure GOLD 4? FEV1 64. Figure Brazil Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
65. Figure Argentina Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
66. Figure Rest of Latin America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
67. Figure Short-Acting Bronchodilators Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

68. Figure Corticosteroids Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

69. Figure Methylxanthines Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Gr

I would like to order

Product name: Drugs for Chronic Obstructive Pulmonary Disorder Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

Product link: <https://marketpublishers.com/r/D51CC2175ECFEN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D51CC2175ECFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

